In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteria

J. H. Jorgensen; L. A. Maher; J. S. Redding

doi:10.1007/BF02097209

In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteria

J. H. Jorgensen, L. A. Maher, J. S. Redding

Department of Pathology

Resultado de la investigación: Article › revisión exhaustiva

13 Citas (Scopus)

Resumen

The in vitro activity of the new lipopeptide antibiotic LY146032 was generally four-fold greater (MIC 90 ≤ 0. 5 μg/ml) than that of vancomycin against methicillin-susceptible or methicillin-resistant Staphybcoccus aureus and coagulase-negative species of Staphylococcus. Enterococci, Streptococcus bovis, group B and viridans streptococci, and Corynebacterium group J-K isolates were inhibited by ≤ 4 μg/ml of LY146032, which represented activity equivalent to or greater than that of vancomycin. Unlike vancomycin, LY146032 was bactericidal for Enterococcus faecalis, Enterococcus faecium and Listeria monocytogenes. Due to its bactericidal properties LY146032 appeared to represent an improvement over vancomycin and teicoplanin.

Idioma original	English (US)
Páginas (desde-hasta)	91-96
Número de páginas	6
Publicación	European Journal of Clinical Microbiology
Volumen	6
N.º	1
DOI	https://doi.org/10.1007/BF02097209
Estado	Published - feb 1 1987

ASJC Scopus subject areas

Microbiology
Microbiology (medical)

Acceder al documento

10.1007/BF02097209

Otros archivos y enlaces

Citar esto

@article{c09071c4aeee4c959890f43179469af6,

title = "In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteria",

abstract = "The in vitro activity of the new lipopeptide antibiotic LY146032 was generally four-fold greater (MIC 90 ≤ 0. 5 μg/ml) than that of vancomycin against methicillin-susceptible or methicillin-resistant Staphybcoccus aureus and coagulase-negative species of Staphylococcus. Enterococci, Streptococcus bovis, group B and viridans streptococci, and Corynebacterium group J-K isolates were inhibited by ≤ 4 μg/ml of LY146032, which represented activity equivalent to or greater than that of vancomycin. Unlike vancomycin, LY146032 was bactericidal for Enterococcus faecalis, Enterococcus faecium and Listeria monocytogenes. Due to its bactericidal properties LY146032 appeared to represent an improvement over vancomycin and teicoplanin.",

author = "Jorgensen, {J. H.} and Maher, {L. A.} and Redding, {J. S.}",

year = "1987",

month = feb,

day = "1",

doi = "10.1007/BF02097209",

language = "English (US)",

volume = "6",

pages = "91--96",

journal = "European Journal of Clinical Microbiology and Infectious Diseases",

issn = "0934-9723",

publisher = "Vieweg",

number = "1",

}

TY - JOUR

T1 - In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteria

AU - Jorgensen, J. H.

AU - Maher, L. A.

AU - Redding, J. S.

PY - 1987/2/1

Y1 - 1987/2/1

N2 - The in vitro activity of the new lipopeptide antibiotic LY146032 was generally four-fold greater (MIC 90 ≤ 0. 5 μg/ml) than that of vancomycin against methicillin-susceptible or methicillin-resistant Staphybcoccus aureus and coagulase-negative species of Staphylococcus. Enterococci, Streptococcus bovis, group B and viridans streptococci, and Corynebacterium group J-K isolates were inhibited by ≤ 4 μg/ml of LY146032, which represented activity equivalent to or greater than that of vancomycin. Unlike vancomycin, LY146032 was bactericidal for Enterococcus faecalis, Enterococcus faecium and Listeria monocytogenes. Due to its bactericidal properties LY146032 appeared to represent an improvement over vancomycin and teicoplanin.

AB - The in vitro activity of the new lipopeptide antibiotic LY146032 was generally four-fold greater (MIC 90 ≤ 0. 5 μg/ml) than that of vancomycin against methicillin-susceptible or methicillin-resistant Staphybcoccus aureus and coagulase-negative species of Staphylococcus. Enterococci, Streptococcus bovis, group B and viridans streptococci, and Corynebacterium group J-K isolates were inhibited by ≤ 4 μg/ml of LY146032, which represented activity equivalent to or greater than that of vancomycin. Unlike vancomycin, LY146032 was bactericidal for Enterococcus faecalis, Enterococcus faecium and Listeria monocytogenes. Due to its bactericidal properties LY146032 appeared to represent an improvement over vancomycin and teicoplanin.

UR - http://www.scopus.com/inward/record.url?scp=0023102328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023102328&partnerID=8YFLogxK

U2 - 10.1007/BF02097209

DO - 10.1007/BF02097209

M3 - Article

C2 - 3032612

AN - SCOPUS:0023102328

SN - 0934-9723

VL - 6

SP - 91

EP - 96

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

IS - 1

ER -

In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteria

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto